4771-76-0

Usage

Uses

Used in Pharmaceutical Research:
1-(6-Methyl-1H-indol-3-yl)propan-2-aMine is used as a research compound for its various pharmacological properties, including its anti-inflammatory, antiviral, and anticancer activities. It is utilized in the development of new drugs and therapies targeting a range of diseases and conditions.
Used in Neurological Disorders Research:
In the field of neurological disorders, 1-(6-Methyl-1H-indol-3-yl)propan-2-aMine is used as a potential therapeutic agent for conditions such as Alzheimer's disease and Parkinson's disease. Its application is based on its ability to modulate biological pathways and mechanisms associated with these disorders, offering a promising avenue for treatment development.
Used in Medicinal Chemistry:
1-(6-Methyl-1H-indol-3-yl)propan-2-aMine is employed in medicinal chemistry as a key intermediate or building block in the synthesis of more complex molecules with potential therapeutic applications. Its unique structure and functional groups make it a valuable component in the design and synthesis of new drugs.

Upstream product

• 3420-02-8 6-methylindole 
• 4771-49-7 6-methyl-1H-indole-3-carboxaldehyde 
• 566200-36-0 6-methyl-3-(2-nitro-propenyl)-1H-indole 

Relevant academic research and scientific papers

α-Methyltryptamine sulfonamide derivatives as novel glucocorticoid receptor ligands

α-Methyltryptamine sulfonamides were identified as human glucocorticoid receptor (hGR) ligands in an ultra high throughput screening (UHTS) campaign. Described will be the hit-to-lead activities, including parallel and single point analog synthesis to map the scaffold. Ligands were identified that exhibited 30 nM binding to hGR. The SAR and selectivity of these compounds will be discussed.

Discovery of a novel and potent human and rat β3-adrenergic receptor agonist, [3-[(2R)-[[(2R)-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl] -1H-indol-7-yloxy]acetic acid

In search for potent and selective β3-adrenergic receptor (β3-AR) agonists as potential drugs for the treatment of type II diabetes and obesity, a novel series of 1-(3-chlorophenyl)-2-aminoethanol derivatives were prepared and evaluated for their biological activity at human β1-, β2-, and β3-ARs and rat β3-AR expressed in Chinese hamster ovary (CHO) cells. Replacement of the right-hand side (RHS, benzene ring) in the 'first generation' β3-AR agonists BRL 37344 and CL 316243 with a 1H-indole ring gave compound 31 with unique pharmacological properties among β3-AR agonists. Initial in vitro assays showed that 31 possesses modest rat and human β3-ARs agonistic activity. Introduction of various substituent into the indole nucleus of 31 afforded a number of compounds with good β3-ARs agonistic activity. In particular, 90 having a carboxylic acid functionality at the 7-position of the indole nucleus showed the most potent human β3-AR agonistic activity. Finally, optical resolution of 90 led to the identification of the most promising compound, [3-[(2R)-[[(2R)-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1H- indol-7-yloxy]acetic acid (96, AJ-9677). This compound exhibited potent human β3-AR agonistic activity (EC50 = 0.062 nM, IA = 116%) with 210- and 103-fold selectivity over human β2-AR and β1-AR, respectively. Compound 96 also exhibited potent rat β3-AR agonistic activity (EC50 = 0.016 nM, IA = 110%). Moreover, repeated oral administration of 96 inhibited body weight gain and significantly decreased glucose, insulin, free fatty acid, and triglyceride concentrations in plasma in KK-Ay/Ta mice. On the basis of this pharmacological profile, 96 entered clinical development as a drug for the treatment of type II diabetes and obesity.

Novel and potent human and rat β3-adrenergic receptor agonists containing substituted 3-indolylalkylamines

A novel series of 2-(3-indolyl)alkylamino-1-(3-chlorophenyl)ethanols was prepared and evaluated for in vitro ability to stimulate cAMP production in Chinese hamster ovary cells expressing cloned human β3-AR. The optically active 30a was found to be the most potent and selective human β3-AR agonist in this series with an EC50 value of 0.062 nM. In addition, 30a selectivity for human β3-AR was 210-fold and 103-fold that for human β2-AR and β1-AR, respectively. Furthermore, 30a showed potent agonistic activity at rat β3-AR.